Eli Lilly News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

20.09.23	Eli Lilly Sues Clinics Over Unauthorized Mounjaro Drug Sale (RTTNews)
29.08.23	Lilly to Participate in Morgan Stanley 21st Annual Global Healthcare Conference (PR Newswire)
22.08.23	Eli Lilly Says LIBRETTO-531 Study Evaluating Retevmo Meets Primary Endpoint (RTTNews)
22.08.23	Lilly's Retevmo® (selpercatinib) Demonstrates Superior Progression-Free Survival Compared to Approved Multikinase Inhibitors in RET-Mutant Medullary Thyroid Cancer (PR Newswire)
14.08.23	Eli Lilly Completes Acquisition Of Versanis Bio (RTTNews)
14.08.23	Lilly Completes Acquisition of Versanis Bio (PR Newswire)
14.08.23	Eli Lilly Concludes Acquisition Of Sigilon Therapeutics (RTTNews)
14.08.23	Lilly Completes Acquisition of Sigilon Therapeutics (PR Newswire)
09.08.23	Lilly Completes Acquisition of DICE Therapeutics (PR Newswire)
08.08.23	Eli Lilly Boosts Outlook As Q2 Results Top Estimates; Stock Up 11% (RTTNews)
08.08.23	Eli Lilly Up Over 11% In Pre-market After Increased Q2 Profit, Outlook (RTTNews)
08.08.23	Eli Lilly Boosts FY23 Outlook - Update (RTTNews)
08.08.23	Eli Lilly And Co. Q2 Profit Increases, beats estimates (RTTNews)
08.08.23	Lilly Reports Second-Quarter 2023 Financial Results, Highlights Accelerating Revenue Growth and Key Pipeline Advancements (PR Newswire)
04.08.23	Eli Lilly: LIBRETTO-431 Study Meets Primary Endpoint (RTTNews)
04.08.23	Lilly's Retevmo® (selpercatinib) is the First Targeted Therapy to Demonstrate Superior Progression-Free Survival Compared to a PD-1 Inhibitor Plus Chemotherapy for Adults with Newly-Diagnosed Adva... (PR Newswire)
27.07.23	Lilly's Diabetes Drug Tirzepatide Demonstrates Significant And Superior Weight Loss In Two Studies (RTTNews)
27.07.23	Tirzepatide demonstrated significant and superior weight loss compared to placebo in two pivotal studies (PR Newswire)
25.07.23	Lilly Confirms Date and Conference Call for Second-Quarter 2023 Financial Results Announcement (PR Newswire)
25.07.23	Lilly Extends Tender Offer To Acquire DICE (RTTNews)
25.07.23	Lilly Announces Extension of Tender Offer to Acquire DICE (PR Newswire)
18.07.23	Lilly Says Its Alzheimer's Drug Significantly Slowed Cognitive And Functional Decline (RTTNews)
17.07.23	Results from Lilly's Landmark Phase 3 Trial of Donanemab Presented at Alzheimer's Association Conference and Published in JAMA (PR Newswire)
17.07.23	Sangamo Inks Evaluation And Option Agreement With Lilly's Prevail For Adeno-associated Virus Capsids (RTTNews)
14.07.23	Eli Lilly To Acquire Versanis Bio - Quick Facts (RTTNews)
14.07.23	Lilly to Acquire Versanis to Improve Patient Outcomes in Cardiometabolic Diseases (PR Newswire)
11.07.23	Lilly Announces Webcast to Provide Alzheimer's Disease Update at AAIC (PR Newswire)
06.07.23	New England Journal of Medicine Publishes BRUIN Phase 1/2 Trial Data for Pirtobrutinib in BTK Inhibitor Pre-Treated Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (PR Newswire)
29.06.23	Eli Lilly To Acquire Sigilon Therapeutics (RTTNews)
29.06.23	Lilly to Acquire Sigilon Therapeutics (PR Newswire)
27.06.23	Eli Lilly's Obesity Drug Retatrutide Leads To 24.2% Weight Loss In Phase 2 Trial (RTTNews)
27.06.23	Lilly's phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity... (PR Newswire)
26.06.23	Lilly Declares Third-Quarter 2023 Dividend (PR Newswire)
24.06.23	Lilly's SURMOUNT-2 results published in The Lancet show tirzepatide achieved a mean weight reduction of 15.7% at the highest dose (15 mg) in adults with obesity or overweight and type 2 diabetes (PR Newswire)
24.06.23	Lilly's phase 2 results published in the New England Journal of Medicine show orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved up to 14.7% mean weight reduction at 36 we... (PR Newswire)
21.06.23	US FDA approves Jardiance® (empagliflozin) for the treatment of type 2 diabetes in children 10 years and older (PR Newswire)
21.06.23	FDA Approves Boehringer Ingelheim' Jardiance And Synjardy To Treat Pediatric Type 2 Diabetes (RTTNews)
20.06.23	Lilly to present new research in the treatment of diabetes and obesity at the American Diabetes Association's® 83rd Scientific Sessions (PR Newswire)
20.06.23	Lilly Teams up with the American Diabetes Association and Adam Duvall to Launch "Tap the Cap" (PR Newswire)
20.06.23	Eli Lilly To Acquire DICE Therapeutics For $48/share All-cash Deal (RTTNews)
20.06.23	Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology (PR Newswire)
16.06.23	First-Of-Its-Kind Head-to-Head Clinical Trial Reaffirms the Efficacy of Emgality in Episodic Migraine Prevention (PR Newswire)
02.06.23	Lilly Highlights Verzenio® (abemaciclib) and Jaypirca™ (pirtobrutinib) Data at 2023 ASCO® Annual Meeting (PR Newswire)
30.05.23	Lilly to Participate in Goldman Sachs Global Healthcare Conference (PR Newswire)
22.05.23	Lilly ESG Report Highlights Progress Towards Sustainability Goals (PR Newswire)
18.05.23	Lilly's peresolimab Phase 2a rheumatoid arthritis trial published in The New England Journal of Medicine (PR Newswire)
11.05.23	Loxo@Lilly Announces Details of Presentations at 2023 European Hematology Association (EHA) Annual Meeting (PR Newswire)
09.05.23	Lilly's Social Impact Venture Capital Portfolio Poised to Grow to $300 Million with New $50 Million Allocation (PR Newswire)
09.05.23	Eli Lilly Reports Interim Results From The Phase 2 Study Of Mirikizumab (RTTNews)
09.05.23	Lilly Discloses First-in-Class, Interim Phase 2 Data in Pediatric Patients and New Analysis from Phase 3 Program in Adult Patients for Mirikizumab in Ulcerative Colitis (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

29.12.24		Novartis-Aktie: Novartis muss sich erneut Schmiergeld-Vorwürfen stellen
27.12.24		Anleger in New York halten sich zurück: Dow Jones beendet die Freitagssitzung im Minus
27.12.24		BioNTech und Pfizer zahlen Milliardenbetrag für Impfstoffvergleich in USA - BioNTech-Aktie fester
27.12.24		Börse Europa: Euro STOXX 50 verbucht zum Ende des Freitagshandels Zuschläge
27.12.24		SLI-Handel aktuell: Zum Handelsende Gewinne im SLI
27.12.24		Freitagshandel in Frankfurt: LUS-DAX zeigt sich letztendlich fester
27.12.24		Börse Frankfurt: DAX zum Handelsende auf grünem Terrain
27.12.24		Optimismus in Zürich: SMI zum Ende des Freitagshandels mit grünem Vorzeichen

29.12.24

Novartis-Aktie: Novartis muss sich erneut Schmiergeld-Vorwürfen stellen

27.12.24

Anleger in New York halten sich zurück: Dow Jones beendet die Freitagssitzung im Minus

27.12.24

BioNTech und Pfizer zahlen Milliardenbetrag für Impfstoffvergleich in USA - BioNTech-Aktie fester

27.12.24

Börse Europa: Euro STOXX 50 verbucht zum Ende des Freitagshandels Zuschläge

27.12.24

SLI-Handel aktuell: Zum Handelsende Gewinne im SLI

27.12.24

Freitagshandel in Frankfurt: LUS-DAX zeigt sich letztendlich fester

27.12.24

Börse Frankfurt: DAX zum Handelsende auf grünem Terrain

27.12.24

Optimismus in Zürich: SMI zum Ende des Freitagshandels mit grünem Vorzeichen

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Eli Lilly

Aktien Top/Flop

Eli Lilly Peer Group Nachrichten

Meistgelesene Nachrichten